EAM Investors’s AnaptysBio ANAB Stock Holding History

EAM Investors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-40,392	Closed	-$1.4M	–	275
2021 Q4	$1.4M	Buy	+40,392	New	+$1.28M	0.23%	212
2018 Q2	–	Sell	-17,023	Closed	-$1.77M	–	288
2018 Q1	$1.77M	Sell	17,023 -2,268	-12%	-$256K	0.3%	152
2017 Q4	$1.94M	Buy	+19,291	New	+$1.42M	0.35%	134

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM Investors's ANAB Position: Q1 2022 in Review

EAM Investors sold out of AnaptysBio (ANAB) in Q1 2022, closing a stake of 40,392 shares — an estimated $1.4M sold.

EAM Investors first reported a position in ANAB in Q4 2017 and held it in 3 quarters. The position peaked at $1.94M in Q4 2017. 131 funds tracked by Wall St. Rank hold ANAB as of Q1 2022.

EAM Investors reported no remaining AnaptysBio position as of Q1 2022 after selling out during the quarter.
EAM Investors sold 40,392 AnaptysBio shares in Q1 2022, an estimated $1.4M.
EAM Investors first reported a position in AnaptysBio in Q4 2017 and held it in 3 quarters.
EAM Investors's AnaptysBio position peaked at $1.94M in Q4 2017.
131 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2022.

Based on EAM Investors's 13F filing for Q1 2022, filed 13 May 2022.